fda approved semaglutide for weight loss Approves Oral Semaglutide: First GLP-1 Pill FDA approves obesity drug that

Ethics declarations Competing interests E.A.S

The STEP trials provide strong evidence that semaglutide 2.4 mg reduces body weight and improves numerous health complications associated with obesity

Large-scale research data, including pooled data from three randomized double-blind placebo-controlled cardiovascular outcome trials, and a nationwide Danish registry-based cohort in over 120,000 patients, suggests GLP-1s reduce the incidence of dementia, especially in patients with type 2 diabetes [19]

GLP-1s are medications designed to manage type 2 diabetes, heart disease and obesity by lowering blood sugar and A1C, interacting with the hunger part of the brain to suppress the appetite and slowing down the process of food emptying from the stomach, causing patients to feel full longer